FEMY

+ Watchlist + Portfolio

Femasys Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $2.71
52-Week Range: $2.02 – $22.20
Market Cap: $21.93M
P/E (TTM): —
EPS (TTM): -2.72
Dividend Yield: —

Advanced Metrics

Price/Book: 1.13
PEG Ratio: —
Return on Equity: -424.97%
Return on Assets: -84.23%
Gross Margin: 60.95%
Operating Margin: -1526.66%
Profit Margin: 0.00%
Current Ratio: 2.14
Debt/Equity: 1.19
Total Debt: $4.79M
Free Cash Flow: —
Revenue Growth: -18.90%
Earnings Growth: —
Enterprise Value: $11.47M

FEMY Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$1.21M	$1.07M	$1.63M	$2.29M
Cost of Revenue	$441.94K	$380.07K	$544.90K	$872.40K
Gross Profit	$764.28K	$691.90K	$1.08M	$1.42M
Research & Development	$5.81M	$7.21M	$8.22M	$7.58M
Selling, General & Admin	$5.99M	$7.51M	$10.36M	$11.09M
Operating Expenses	$12.36M	$15.20M	$18.87M	$19.01M
Operating Income	-$11.60M	-$14.51M	-$17.79M	-$17.59M
EBITDA	-$10.49M	-$13.17M	-$16.33M	-$15.89M
Pretax Income	-$11.39M	-$14.24M	-$18.81M	-$18.63M
Income Tax	$6.30K	$4.34K	$9.60K	$1.30K
Net Income	-$11.39M	-$14.25M	-$18.82M	-$18.63M
Diluted EPS	-19.20	-18.60	-17.00	-9.40
Diluted Shares	590750	769218	1.11M	1.98M

FEMY Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$12.96M	$21.72M	$3.45M	$9.27M
Receivables	$77.47K	$98.91K	$488.37K	$616.60K
Inventory	$436.72K	$667.12K	$3.05M	$5.74M
Current Assets	$14.13M	$23.18M	$8.02M	$16.46M
Total Assets	$16.90M	$27.76M	$12.45M	$20.72M
Current Liabilities	$1.53M	$3.05M	$8.58M	$3.64M
Long-Term Debt	—	$4.26M	—	$3.18M
Total Debt	$543.72K	$6.70M	$7.44M	$4.70M
Total Liabilities	$1.65M	$9.40M	$10.14M	$14.85M
Retained Earnings	-$94.13M	-$108.38M	-$127.20M	-$145.83M
Shareholders' Equity	$15.24M	$18.35M	$2.30M	$5.87M
Working Capital	$12.60M	$20.12M	-$560.42K	$12.82M
Net Debt	—	—	$1.95M	—

FEMY Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$10.73M	-$11.28M	-$19.44M	-$18.69M
Capital Expenditure	-$407.48K	-$143.92K	-$847.76K	-$630.10K
Free Cash Flow	-$11.14M	-$11.42M	-$20.29M	-$19.32M
Depreciation & Amortisation	$889.14K	$907.99K	$872.00K	$850.46K
Stock-Based Compensation	$224.94K	$675.70K	$444.15K	$790.14K
Investing Cash Flow	-$407.48K	-$143.92K	-$847.76K	-$630.10K
Financing Cash Flow	-$681.64K	$20.18M	$2.03M	$25.14M
Net Change in Cash	-$11.82M	$8.75M	-$18.26M	$5.81M

FEMY Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$341.26K	$409.27K	$729.39K	$813.39K	$424.89K
Cost of Revenue	$117.27K	$158.17K	$293.84K	$303.13K	$158.61K
Gross Profit	$224.00K	$251.10K	$435.56K	$510.26K	$266.28K
Research & Development	$2.97M	$1.41M	$1.38M	$1.81M	$1.31M
Selling, General & Admin	$2.63M	$2.60M	$2.62M	$3.24M	$3.10M
Operating Expenses	$5.68M	$4.10M	$4.09M	$5.13M	$4.49M
Operating Income	-$5.46M	-$3.85M	-$3.65M	-$4.62M	-$4.22M
EBITDA	-$5.22M	-$3.88M	-$3.45M	-$3.33M	$1.22M
Pretax Income	-$5.90M	-$4.59M	-$4.19M	-$3.94M	$846.10K
Income Tax	-$4.19K	$0.00	$0.00	$5.49K	$0.00
Net Income	-$5.90M	-$4.59M	-$4.19M	-$3.95M	$846.10K
Diluted EPS	-4.60	-3.20	-2.00	—	0.00
Diluted Shares	1.26M	1.44M	2.05M	—	3.90M

FEMY Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$3.82M	$3.22M	$4.57M	$9.27M	$5.39M
Receivables	$233.60K	$254.58K	$572.20K	$616.60K	$172.26K
Inventory	$3.86M	$5.23M	$5.78M	$5.74M	$6.11M
Current Assets	$9.13M	$9.75M	$12.25M	$16.46M	$12.34M
Total Assets	$13.28M	$13.78M	$16.29M	$20.72M	$16.50M
Current Liabilities	$9.84M	$10.96M	$10.54M	$3.64M	$3.16M
Long-Term Debt	—	—	—	$3.18M	$3.34M
Total Debt	$7.67M	$7.85M	$8.43M	$4.70M	$4.73M
Total Liabilities	$11.28M	$12.27M	$11.73M	$14.85M	$9.21M
Retained Earnings	-$133.10M	-$137.68M	-$141.88M	-$145.83M	-$144.98M
Shareholders' Equity	$2.00M	$1.51M	$4.56M	$5.87M	$7.29M
Working Capital	-$708.87K	-$1.21M	$1.71M	$12.82M	$9.19M
Net Debt	$1.94M	$2.86M	$2.21M	—	—

FEMY Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$4.77M	-$4.35M	-$5.39M	-$4.19M	-$4.14M
Capital Expenditure	-$96.61K	-$96.96K	-$239.82K	-$196.72K	-$79.14K
Free Cash Flow	-$4.86M	-$4.45M	-$5.63M	-$4.38M	-$4.22M
Depreciation & Amortisation	$217.06K	$214.90K	$211.08K	$207.42K	$200.45K
Stock-Based Compensation	$367.24K	$181.97K	$174.51K	$66.42K	$151.61K
Investing Cash Flow	-$96.61K	-$96.96K	-$239.82K	-$196.72K	-$79.14K
Financing Cash Flow	$5.23M	$3.85M	$6.98M	$9.08M	$342.33K
Net Change in Cash	$368.45K	-$602.14K	$1.35M	$4.70M	-$3.88M

Market Snapshot

About

Femasys Inc. is a biomedical company focused on women's healthcare, developing and commercializing innovative products for reproductive health. The company's lead product, FemBloc, is a permanent birth control solution designed as a non-surgical alternative to tubal ligation. Femasys also developed FemaSeed, an artificial insemination catheter system for infertility treatment. The company's technology platform enables minimally invasive procedures that can be performed in an office setting without general anesthesia. Based in Suwanee, Georgia, Femasys aims to address unmet needs in women's reproductive healthcare with products that offer improved safety, convenience, and patient experience compared to traditional surgical approaches.